Amedeo A. Azizi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amedeo A. Azizi has a total of 627 co-authors. Here are the top co-authors by number of shared publications:
- Maura Massimino
Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
52 shared publications Monika Warmuth-Metz
52 shared publications- Darren Hargrave
UCL Great Ormond Street Institute of Child Health, University College London, London, UK
51 shared publications Frank Saran
51 shared publicationsGilles Vassal
51 shared publications- Paul Simon Morgan
Mental Health and Clinical Neuroscience, School of Medicine, University of Nottingham, United Kingdom
51 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 61 (4) , 124-125
Zwischen häufigen Befunden und seltenen Diagnosen
- 11 September 2026
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 61 (4) , 124-125
Open AccessZwischen häufigen Befunden und seltenen Diagnosen
- Open Access
- 12 November 2025
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 61 (4) , 1-6
Ich seh’, ich seh’, was Du (noch) nicht siehst!
Zusammenfassung: Tumoren der Wirbelsäule und des Rückenmarks sind bei Kindern und Jugendlichen zwar selten, haben aber massive Auswirkungen auf die Betroffenen. Die klinische Symptomatik hängt von der Lokalisation des Tumors sowie vom Entwicklungsstadium des Kindes ab. Symptome können in ihrer Ausprägung schwanken, ein unauffälliger neurologischer Untersuchungsbefund schließt einen Tumor nicht aus. Persistierende Symptome müssen weiter abgeklärt werden. Eine frühe Diagnose ist entscheidend, da sie das funktionelle Outcome und die Lebensqualität der betroffenen Kinder deutlich verbessern kann. Bei klinischem Verdacht sollte eine dringliche MRT-Untersuchung erfolgen. Bei jüngeren Kindern kann hierfür eine Narkose erforderlich sein. Nach Diagnosestellung muss sofort der Transfer an ein spezialisiertes interdisziplinäres Zentrum erfolgen, in dem eine umfassende interdisziplinäre Expertise für die Betreuung und Behandlung dieser Kinder und Jugendlichen gebündelt ist.
- 12 November 2025
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 61 (4) , 1-6
Open AccessIch seh’, ich seh’, was Du (noch) nicht siehst!
Zusammenfassung: Tumoren der Wirbelsäule und des Rückenmarks sind bei Kindern und Jugendlichen zwar selten, haben aber massive Auswirkungen auf die Betroffenen. Die klinische Symptomatik hängt von der Lokalisation des Tumors sowie vom Entwicklungsstadium des Kindes ab. Symptome können in ihrer Ausprägung schwanken, ein unauffälliger neurologischer Untersuchungsbefund schließt einen Tumor nicht aus. Persistierende Symptome müssen weiter abgeklärt werden. Eine frühe Diagnose ist entscheidend, da sie das funktionelle Outcome und die Lebensqualität der betroffenen Kinder deutlich verbessern kann. Bei klinischem Verdacht sollte eine dringliche MRT-Untersuchung erfolgen. Bei jüngeren Kindern kann hierfür eine Narkose erforderlich sein. Nach Diagnosestellung muss sofort der Transfer an ein spezialisiertes interdisziplinäres Zentrum erfolgen, in dem eine umfassende interdisziplinäre Expertise für die Betreuung und Behandlung dieser Kinder und Jugendlichen gebündelt ist.
- 7 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 71-85
Pediatric high-grade gliomas in patients with neurofibromatosis type 1—A collaborative cohort study from the SIOPE HGG/DIPG working group
Abstract Background: We assessed clinical features, treatment, and survival of pediatric patients with neurofibromatosis type 1 (NF1) with high-grade glioma (HGG). Methods: Patients from this retrospective cohort study were identified through an international collaborative effort by the SIOPE HGG/DIPG working group. NF1 was diagnosed based on clinical presentation and confirmed by either a pathogenic germline NF1 gene alteration or the exclusion of mismatch repair deficiency. A control cohort without genetic cancer predisposition was matched in a 2:1-ratio from the HIT-HGG database. Results: We identified 29 pediatric patients with NF1-associated HGG. Median age at diagnosis of HGG was 11 years. All but 1 tumor arose outside the optic pathway and included circumscribed and diffuse HGG. Molecular analysis in a subset of tumors identified an enrichment of alterations in CDKN2A, TP53, and ATRX. Event-free and overall survival were as poor as in matched sporadic HGG patients. The prognosis was not superior with upfront radiotherapy compared with delayed radiotherapy. Conclusions: NF1-associated HGGs behave as aggressively as their sporadic counterparts. The relevance of delaying radiotherapy until the time of progression and adjuvant MEK inhibitor treatment needs further investigation.
- 7 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (1) , 71-85
Pediatric high-grade gliomas in patients with neurofibromatosis type 1—A collaborative cohort study from the SIOPE HGG/DIPG working group
Abstract Background: We assessed clinical features, treatment, and survival of pediatric patients with neurofibromatosis type 1 (NF1) with high-grade glioma (HGG). Methods: Patients from this retrospective cohort study were identified through an international collaborative effort by the SIOPE HGG/DIPG working group. NF1 was diagnosed based on clinical presentation and confirmed by either a pathogenic germline NF1 gene alteration or the exclusion of mismatch repair deficiency. A control cohort without genetic cancer predisposition was matched in a 2:1-ratio from the HIT-HGG database. Results: We identified 29 pediatric patients with NF1-associated HGG. Median age at diagnosis of HGG was 11 years. All but 1 tumor arose outside the optic pathway and included circumscribed and diffuse HGG. Molecular analysis in a subset of tumors identified an enrichment of alterations in CDKN2A, TP53, and ATRX. Event-free and overall survival were as poor as in matched sporadic HGG patients. The prognosis was not superior with upfront radiotherapy compared with delayed radiotherapy. Conclusions: NF1-associated HGGs behave as aggressively as their sporadic counterparts. The relevance of delaying radiotherapy until the time of progression and adjuvant MEK inhibitor treatment needs further investigation.
- Open Access
- 18 November 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (3) , 811-827
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Background: Diffuse hemispheric glioma, H3 G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of alpha-thalassemia/mental retardation syndrome X-linked protein (ATRX; DHG-H3G34R_ATRX) suggesting a unique interaction of these 2 oncogenic alterations. In this study, we dissect their cell biological interplay, investigate the impact on telomere stabilization, and consequently validate a targeted therapy approach. Methods: We characterized patient-derived primary pediatric high-grade glioma (pHGG) models for telomere-maintenance mechanisms, DNA damage stress (including protein expression, pH2AX/Rad51 foci, cell-cycle arrest) and their sensitivity towards poly-ADP ribose polymerase inhibitor (PARPi) combinations. Human induced pluripotent stem cells (iPSCs) were used for modeling the disease. The anticancer activity of PARPi combinations in vivo was studied in Chorioallantoic Membrane (CAM) and orthotopic in vivo experiments. Finally, we treated a DHG-H3G34R_ATRX patient with PARPi combination therapy. Results: We elaborate that alternative lengthening of telomeres (ALT) is a key characteristic of DHG-H3G34R_ATRX. A dominant cooperative effect between H3G34R and ATRX loss in ALT activation also became apparent in iPSCs, which endogenously exert telomerase activity. In both, patient-derived DHG-H3G34R_ATRX models and H3G34R+/ATRX- iPSCs, the ALT-phenotype was associated with increased basal DNA damage stress, mediating synergistic susceptibility towards PARPi (talazoparib, niraparib) combinations with topoisomerase-I inhibitors (topotecan, irinotecan). In a first-of-its-kind case, treatment of a DHG-H3G34R_ATRX patient with the brain-penetrant PARP inhibitor niraparib and topotecan resulted in significant tumor reduction. Conclusions: Our preclinical and clinical data strongly support the further development of PARPi together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX.
- 18 November 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (3) , 811-827
Open AccessAlternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Background: Diffuse hemispheric glioma, H3 G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of alpha-thalassemia/mental retardation syndrome X-linked protein (ATRX; DHG-H3G34R_ATRX) suggesting a unique interaction of these 2 oncogenic alterations. In this study, we dissect their cell biological interplay, investigate the impact on telomere stabilization, and consequently validate a targeted therapy approach. Methods: We characterized patient-derived primary pediatric high-grade glioma (pHGG) models for telomere-maintenance mechanisms, DNA damage stress (including protein expression, pH2AX/Rad51 foci, cell-cycle arrest) and their sensitivity towards poly-ADP ribose polymerase inhibitor (PARPi) combinations. Human induced pluripotent stem cells (iPSCs) were used for modeling the disease. The anticancer activity of PARPi combinations in vivo was studied in Chorioallantoic Membrane (CAM) and orthotopic in vivo experiments. Finally, we treated a DHG-H3G34R_ATRX patient with PARPi combination therapy. Results: We elaborate that alternative lengthening of telomeres (ALT) is a key characteristic of DHG-H3G34R_ATRX. A dominant cooperative effect between H3G34R and ATRX loss in ALT activation also became apparent in iPSCs, which endogenously exert telomerase activity. In both, patient-derived DHG-H3G34R_ATRX models and H3G34R+/ATRX- iPSCs, the ALT-phenotype was associated with increased basal DNA damage stress, mediating synergistic susceptibility towards PARPi (talazoparib, niraparib) combinations with topoisomerase-I inhibitors (topotecan, irinotecan). In a first-of-its-kind case, treatment of a DHG-H3G34R_ATRX patient with the brain-penetrant PARP inhibitor niraparib and topotecan resulted in significant tumor reduction. Conclusions: Our preclinical and clinical data strongly support the further development of PARPi together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX.
- Open Access
- 17 October 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (12) , 1526-1541
ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management
Constitutional mismatch repair deficiency (CMMRD), first described 25 years ago, confers an extremely high and lifelong cancer risk, including haematologic, brain, and gastrointestinal tract malignancies, and is associated with several non-neoplastic features. Our understanding of this condition has improved and novel assays to assist CMMRD diagnosis have been developed. Surveillance protocols need adjustment taking into account recent observational prospective studies assessing their effectiveness. Response to immune checkpoint inhibitors and the effectiveness and toxicity of other treatments have been described. An update and merging of the different guidelines on diagnosis and clinical management of CMMRD into one comprehensive guideline was needed. Seventy-two expert members of the European Reference Network GENTURIS and/or the European care for CMMRD consortium and one patient representative developed recommendations for CMMRD diagnosis, genetic counselling, surveillance, quality of life, and clinical management based on a systematic literature search and comprehensive literature review and a modified Delphi process. Recommendations for the diagnosis of CMMRD provide testing criteria, propose strategies for CMMRD testing, and define CMMRD diagnostic criteria. Recommendations for surveillance cover each CMMRD-associated tumour type and contain information on starting age, frequency, and surveillance modality. Recommendations for clinical management cover cancer treatment, management of benign tumours or non-neoplastic features, and chemoprevention. Recommendations also address genetic counselling and quality of life. Based on existing guidelines and currently available data, we present 82 recommendations to improve and standardise the care of CMMRD patients in Europe. These recommendations are not meant to be prescriptive and may be adjusted based on individual decisions.
- 17 October 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (12) , 1526-1541
Open AccessERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management
Constitutional mismatch repair deficiency (CMMRD), first described 25 years ago, confers an extremely high and lifelong cancer risk, including haematologic, brain, and gastrointestinal tract malignancies, and is associated with several non-neoplastic features. Our understanding of this condition has improved and novel assays to assist CMMRD diagnosis have been developed. Surveillance protocols need adjustment taking into account recent observational prospective studies assessing their effectiveness. Response to immune checkpoint inhibitors and the effectiveness and toxicity of other treatments have been described. An update and merging of the different guidelines on diagnosis and clinical management of CMMRD into one comprehensive guideline was needed. Seventy-two expert members of the European Reference Network GENTURIS and/or the European care for CMMRD consortium and one patient representative developed recommendations for CMMRD diagnosis, genetic counselling, surveillance, quality of life, and clinical management based on a systematic literature search and comprehensive literature review and a modified Delphi process. Recommendations for the diagnosis of CMMRD provide testing criteria, propose strategies for CMMRD testing, and define CMMRD diagnostic criteria. Recommendations for surveillance cover each CMMRD-associated tumour type and contain information on starting age, frequency, and surveillance modality. Recommendations for clinical management cover cancer treatment, management of benign tumours or non-neoplastic features, and chemoprevention. Recommendations also address genetic counselling and quality of life. Based on existing guidelines and currently available data, we present 82 recommendations to improve and standardise the care of CMMRD patients in Europe. These recommendations are not meant to be prescriptive and may be adjusted based on individual decisions.
- Open Access
- 7 May 2024
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 174 (S1) , 61-62
Publisher Erratum: Neurofibromatose Typ 1: Vorsorgebogen für Kinder und Jugendliche in Österreich
- 7 May 2024
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 174 (S1) , 61-62
Open AccessPublisher Erratum: Neurofibromatose Typ 1: Vorsorgebogen für Kinder und Jugendliche in Österreich
- Top Cited PapersOpen Access
- 27 April 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 11 (5) , 515-531
Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
Background: Selumetinib is the first approved treatment for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in the EU and US, as well as in multiple other countries. Evidence for the management of selumetinib-associated adverse events (AEs) is mostly limited to clinical trials and expanded-access programs. We gathered a panel of European healthcare practitioners with clinical experience prescribing selumetinib and/or managing pediatric patients with NF1-PN to provide recommendations on the prevention and management of AEs. Methods: A modified Delphi approach was used to develop the recommendations among the group of experts. Initial statements were developed from a literature review of current management recommendations and regulatory reports. The panel refined the statements and rated the extent to which they agreed with them in 2 sessions and a follow-up survey. The panel comprised 2 pediatric neuro-oncologists, 1 pediatric oncologist, 1 pediatrician, 1 neuropediatrician, 1 oncologist, 1 neurologist, 2 psychologists, and 1 dermatologist. Results: The experts agreed on the relative frequency and impact of AEs potentially associated with selumetinib. Consensus-level agreement was reached for 36 statements regarding the prevention and management of AEs potentially associated with selumetinib. Experts recommended treatments for AEs based on their experience. Conclusions: The development of a variety of consensus statements indicates expert agreement on best practices for the prevention and management of AEs potentially associated with selumetinib in pediatric patients with NF1-PN. These events are generally manageable and should be considered alongside treatment benefit. Information sharing is warranted as further experience is gained.
- 27 April 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 11 (5) , 515-531
Top Cited PapersOpen AccessConsensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
Background: Selumetinib is the first approved treatment for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in the EU and US, as well as in multiple other countries. Evidence for the management of selumetinib-associated adverse events (AEs) is mostly limited to clinical trials and expanded-access programs. We gathered a panel of European healthcare practitioners with clinical experience prescribing selumetinib and/or managing pediatric patients with NF1-PN to provide recommendations on the prevention and management of AEs. Methods: A modified Delphi approach was used to develop the recommendations among the group of experts. Initial statements were developed from a literature review of current management recommendations and regulatory reports. The panel refined the statements and rated the extent to which they agreed with them in 2 sessions and a follow-up survey. The panel comprised 2 pediatric neuro-oncologists, 1 pediatric oncologist, 1 pediatrician, 1 neuropediatrician, 1 oncologist, 1 neurologist, 2 psychologists, and 1 dermatologist. Results: The experts agreed on the relative frequency and impact of AEs potentially associated with selumetinib. Consensus-level agreement was reached for 36 statements regarding the prevention and management of AEs potentially associated with selumetinib. Experts recommended treatments for AEs based on their experience. Conclusions: The development of a variety of consensus statements indicates expert agreement on best practices for the prevention and management of AEs potentially associated with selumetinib in pediatric patients with NF1-PN. These events are generally manageable and should be considered alongside treatment benefit. Information sharing is warranted as further experience is gained.
- Open Access
- 16 April 2024
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 173 (8) , 662-669
Neurofibromatose Typ 1: Vorsorgebogen für Kinder und Jugendliche in Österreich
Zusammenfassung: Hintergrund: Neurofibromatose Typ 1 (NF1) präsentiert sich bereits im Kindesalter mit einer Vielzahl potenzieller Symptome. Neben der Entstehung von Tumoren, insbesondere im Bereich des Nervensystems, rücken besonders orthopädische, neurokognitive/schulische und psychosoziale Aspekte in den Fokus. Zielsetzung: In Österreich fehlten bisher klare Leitlinien für die Betreuung von Kindern und Jugendlichen mit NF1. Die Entwicklung eines Vorsorgebogens soll ein einheitliches Vorgehen ermöglichen. Methodik: Das im Jahr 2021 etablierte österreichische NF Netzwerk, bestehend aus Expert:innen und Mitgliedern der Patientenorganisation NF Kinder, erzielte durch wiederholte Diskussionsrunden einen Konsens bezüglich der optimalen Vorsorge für Kinder und Jugendliche mit NF1. Der Vorsorgebogen richtet sich an Gesundheitspersonal, das Menschen mit NF1 betreut. Ergebnisse: Der pädiatrische Vorsorgebogen ist in die Bereiche Klinik/Labor/Radiologie und Konsil gegliedert. Er zeigt auf, wann und welche Untersuchungen oder Kontrollen als sinnvoll erachtet bzw. empfohlen werden. Schlussfolgerung: Die Entwicklung dieses Vorsorgebogens stellt einen bedeutenden Schritt in der Standardisierung der Versorgung von Kindern und Jugendlichen mit NF1 in Österreich dar. Durch die einfache Strukturierung und praxisorientierte Empfehlungen sollen eine effektivere Betreuung und Früherkennung von relevanten Gesundheitsaspekten ermöglicht werden.
- 16 April 2024
- Published by Springer Nature in Monatsschrift Kinderheilkunde
- Vol. 173 (8) , 662-669
Open AccessNeurofibromatose Typ 1: Vorsorgebogen für Kinder und Jugendliche in Österreich
Zusammenfassung: Hintergrund: Neurofibromatose Typ 1 (NF1) präsentiert sich bereits im Kindesalter mit einer Vielzahl potenzieller Symptome. Neben der Entstehung von Tumoren, insbesondere im Bereich des Nervensystems, rücken besonders orthopädische, neurokognitive/schulische und psychosoziale Aspekte in den Fokus. Zielsetzung: In Österreich fehlten bisher klare Leitlinien für die Betreuung von Kindern und Jugendlichen mit NF1. Die Entwicklung eines Vorsorgebogens soll ein einheitliches Vorgehen ermöglichen. Methodik: Das im Jahr 2021 etablierte österreichische NF Netzwerk, bestehend aus Expert:innen und Mitgliedern der Patientenorganisation NF Kinder, erzielte durch wiederholte Diskussionsrunden einen Konsens bezüglich der optimalen Vorsorge für Kinder und Jugendliche mit NF1. Der Vorsorgebogen richtet sich an Gesundheitspersonal, das Menschen mit NF1 betreut. Ergebnisse: Der pädiatrische Vorsorgebogen ist in die Bereiche Klinik/Labor/Radiologie und Konsil gegliedert. Er zeigt auf, wann und welche Untersuchungen oder Kontrollen als sinnvoll erachtet bzw. empfohlen werden. Schlussfolgerung: Die Entwicklung dieses Vorsorgebogens stellt einen bedeutenden Schritt in der Standardisierung der Versorgung von Kindern und Jugendlichen mit NF1 in Österreich dar. Durch die einfache Strukturierung und praxisorientierte Empfehlungen sollen eine effektivere Betreuung und Früherkennung von relevanten Gesundheitsaspekten ermöglicht werden.
- Open Access
- 8 April 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (4) , 429-440
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
Background To date, evidence has been lacking regarding bevacizumab pharmacokinetics in the cerebrospinal fluid (CSF). Objective This study assessed the penetration of bevacizumab, as part of a metronomic antiangiogenic treatment regimen, into the CSF of children, adolescents, and young adults with recurrent brain tumors. Patients and Methods Serum and CSF concentrations, malignant cells, and vascular endothelial growth factor A (VEGF-A) were analyzed in 12 patients (5–27 years) following 10 mg/kg bevacizumab intravenous biweekly administration (EudraCT number 2009-013024-23). A population pharmacokinetic model including body weight, albumin, and tumor type as influential factors was extended to quantify the CSF penetration of bevacizumab. Results Apart from in serum (minimum concentration/maximum concentration [Cmin/Cmax] 77.0–305/267–612 mg/L, median 144/417 mg/L), bevacizumab could be quantified in the CSF (0.01–2.26 mg/L, median 0.35 mg/L). The CSF/serum ratio was 0.16 and highly variable between patients. Malignant cells could be detected in CSF before initiation of treatment in five of 12 patients; after treatment, the CSF was cleared in all patients. VEGF-A was detected in three patients before treatment (mean ± SD: 20 ± 11 pg/mL), and was still measurable in one of these patients despite treatment (16 pg/mL). Conclusions This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.
- 8 April 2024
- Published by Springer Nature in Pediatric Drugs
- Vol. 26 (4) , 429-440
Open AccessDistribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
Background To date, evidence has been lacking regarding bevacizumab pharmacokinetics in the cerebrospinal fluid (CSF). Objective This study assessed the penetration of bevacizumab, as part of a metronomic antiangiogenic treatment regimen, into the CSF of children, adolescents, and young adults with recurrent brain tumors. Patients and Methods Serum and CSF concentrations, malignant cells, and vascular endothelial growth factor A (VEGF-A) were analyzed in 12 patients (5–27 years) following 10 mg/kg bevacizumab intravenous biweekly administration (EudraCT number 2009-013024-23). A population pharmacokinetic model including body weight, albumin, and tumor type as influential factors was extended to quantify the CSF penetration of bevacizumab. Results Apart from in serum (minimum concentration/maximum concentration [Cmin/Cmax] 77.0–305/267–612 mg/L, median 144/417 mg/L), bevacizumab could be quantified in the CSF (0.01–2.26 mg/L, median 0.35 mg/L). The CSF/serum ratio was 0.16 and highly variable between patients. Malignant cells could be detected in CSF before initiation of treatment in five of 12 patients; after treatment, the CSF was cleared in all patients. VEGF-A was detected in three patients before treatment (mean ± SD: 20 ± 11 pg/mL), and was still measurable in one of these patients despite treatment (16 pg/mL). Conclusions This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.